Breast Cancer; Lung Cancer; Cancer; Skin Cancer; Personalized Medicine; Gene Therapy; Colon Cancer; Diseases and Conditions

The recent U.S. Food and Drug Administration approval of lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, marks a significant breakthrough in cancer therapy. In a new commentary published in Cancer Cell, Moffitt Cancer Center scientists provide a comprehensive overview of the therapy’s development and highlight its transformative potential. “TIL therapy represents … Read more